Fatigue Assessment and Dose Modification in Prostate Cancer Management

In this segment, Dr. Graham and Dr. Sokolova discuss fatigue management as a common and clinically meaningful adverse effect in patients receiving androgen receptor–targeted therapies for prostate cancer. The conversation highlights how routine assessment of fatigue severity and its impact on daily functioning informs ongoing treatment decisions. Dr. Graham describes practical approaches to evaluating fatigue, including consideration of contributing factors such as comorbidities, concurrent medications, and treatment duration. Both experts emphasize that dose modification can be an important strategy to manage fatigue while maintaining disease control, particularly in patients receiving long-term therapy. The discussion reinforces the importance of individualized assessment, shared decision-making, and close follow-up when adjusting treatment. Overall, this segment provides insight into how clinicians balance symptom management with therapeutic effectiveness in contemporary prostate cancer care.